Effect of 48-week pemafibrate on non-alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan-aspartate aminotransferase score.
Takeshi HatanakaTakashi KosoneNaoto SaitoSatoshi TakakusagiHiroki TojimaAtsushi NaganumaHitoshi TakagiMasashi NamikawaSatoru KakizakiPublished in: JGH open : an open access journal of gastroenterology and hepatology (2021)
Pemafibrate improved the FAST score due to the hepatic anti-inflammatory effect, indicating that pemafibrate may prevent disease progression in NAFLD patients with hypertriglyceridemia.